Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSC) Enterprise Value (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Enterprise Value for 6 consecutive years, with -$2.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value rose 55.34% to -$2.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.0 million, a 55.34% increase, with the full-year FY2024 number at -$3.8 million, down 163.81% from a year prior.
  • Enterprise Value was -$2.0 million for Q3 2025 at Ensysce Biosciences, up from -$2.5 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$18034.0 in Q1 2021 to a low of -$12.5 million in Q4 2021.
  • A 5-year average of -$4.6 million and a median of -$3.7 million in 2024 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: tumbled 48256.35% in 2022, then skyrocketed 80.11% in 2023.
  • Ensysce Biosciences' Enterprise Value stood at -$12.5 million in 2021, then surged by 72.4% to -$3.5 million in 2022, then surged by 58.07% to -$1.5 million in 2023, then crashed by 163.81% to -$3.8 million in 2024, then soared by 47.74% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Enterprise Value are -$2.0 million (Q3 2025), -$2.5 million (Q2 2025), and -$3.4 million (Q1 2025).